AI Summary
This article discusses the occurrence of autoimmune bullous diseases in a cohort of European patients due to the use of cyclin-dependent kinase (CDK) 4/6 inhibitors such as palbociclib and ribociclib. While dermatologic adverse events of CDK 4/6 inhibitors are relatively common, bullous lesions are rare. The study sheds light on this specific side effect in cancer patients using these medications.
Dermatologic adverse events of cyclin-dependent kinase (CDK) 4/6 inhibitors have been reported in ∼15% of patients, the most common being pruritus, alopecia, and eczema-like lesions.1,2 More characteristic cutaneous toxicities include lupus erythematosus and vitiligo-like reactions.2 In contrast, bullous lesions have been exceptionally reported with CDK4/6 inhibitors.1,3-5 Here, we report a cohort of European patients who developed autoimmune bullous diseases induced by palbociclib and ribociclib.